{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:34:27Z","timestamp":1792996467210,"version":"4.5.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>To concisely review the selection of empiric antibiotics, optimization of antibiotic dosing based on pharmacokinetic principles, and antibiotic de-escalation in critically ill patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Empiric therapy decisions should be based on patient risk for multidrug-resistant organisms. Administration of single-agent broad spectrum therapy is generally sufficient and agents with anaerobic activity should be avoided except in patients with specific sources of infection. Prolonged infusions of beta-lactams, therapeutic drug-monitoring, and refinement of historical dosing recommendations should be implemented in most patients to optimize pharmacokinetics in critically ill patients. Antibiotic de-escalation is essential component of antimicrobial stewardship and should be facilitated by consideration of rapid diagnostic test results coupled with evidence of clinical improvement. The duration of antibiotic therapy in most cases should be 1 week or less in patients who have had the antibiotic regimen de-escalated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Given the high prevalence of antibiotic administration, it is imperative to implement evidence-based practices regarding empiric antibiotic selection, dose optimization, and a steadfast commitment to antibiotic de-escalation to enhance patient outcomes given the inevitability of continuing infections due to multidrug-resistant organisms in critically ill patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcc.0000000000001389","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T13:00:07Z","timestamp":1778418007000},"page":"429-435","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Antibiotic use in serious infections"],"prefix":"10.1097","volume":"32","author":[{"given":"Lauren","family":"Kolodziej","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Matuszak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Micek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Center for Health Outcomes Research and Education, University of Health Sciences and Pharmacy, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"R1-20261026","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"R2-20261026","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"R3-20261026","doi-asserted-by":"crossref","first-page":"100902","DOI":"10.1016\/S2666-5247(24)00134-4","article-title":"WHO global research priorities for antimicrobial resistance in human health","volume":"5","author":"Bertagnolio","year":"2024","journal-title":"Lancet Microbe"},{"key":"R4-20261026","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"R5-20261026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejim.2024.06.015","article-title":"Door-to-antibiotic time and mortality in patients with sepsis: systematic review and meta-analysis","volume":"129","author":"Leung","year":"2024","journal-title":"Eur J Intern Med"},{"key":"R6-20261026","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1473-3099(20)30477-1","article-title":"Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals","volume":"21","author":"Kadri","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R7-20261026","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/ciaf118","article-title":"Frequency of antibiotic overtreatment and associated harms in patients presenting with suspected sepsis to the emergency department: a retrospective cohort study","volume":"80","author":"Shappell","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R8-20261026","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/CCM.0000000000007089","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026","volume":"54","author":"Prescott","year":"2026","journal-title":"Crit Care Med"},{"key":"R9-20261026","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"R10-20261026","first-page":"e0383","article-title":"A multicenter observational study evaluating outcomes associated with antibiotic combination versus monotherapy in patients with septic shock","volume":"3","author":"Torisson","year":"2021","journal-title":"Crit Care Explor"},{"key":"R11-20261026","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"R12-20261026","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2016.11.013","article-title":"Empirical mono- versus combination antibiotic therapy in adult intensive care patients with severe sepsis - a systematic review with meta-analysis and trial sequential analysis","volume":"74","author":"Sj\u00f6vall","year":"2017","journal-title":"J Infect"},{"key":"R13-20261026","doi-asserted-by":"crossref","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing Gram-negative pathogens: a phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"R14-20261026","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"R15-20261026","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R16-20261026","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(25)00469-4","article-title":"Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial","volume":"26","author":"Paterson","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"R17-20261026","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"R18-20261026","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","article-title":"Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","volume":"25","author":"Shields","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"R19-20261026","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"R20-20261026","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for Healthcare Professionals From the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"R21-20261026","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R22-20261026","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/sur.2020.436","article-title":"Surgical Infection Society 2020 Updated Guidelines on the management of complicated skin and soft tissue infections","volume":"22","author":"Duane","year":"2021","journal-title":"Surg Infect (Larchmt)"},{"key":"R23-20261026","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2024.0581","article-title":"Mortality of patients with sepsis administered piperacillin-tazobactam vs cefepime","volume":"184","author":"Chanderraj","year":"2024","journal-title":"JAMA Intern Med"},{"key":"R24-20261026","doi-asserted-by":"crossref","first-page":"2200910","DOI":"10.1183\/13993003.00910-2022","article-title":"In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes","volume":"61","author":"Chanderraj","year":"2023","journal-title":"Eur Respir J"},{"key":"R25-20261026","doi-asserted-by":"crossref","first-page":"2300413","DOI":"10.1183\/13993003.00413-2023","article-title":"Empiric anti-anaerobic antibiotics are associated with adverse clinical outcomes in emergency department patients","volume":"61","author":"Kullberg","year":"2023","journal-title":"Eur Respir J"},{"key":"R26-20261026","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1093\/jac\/dkz279","article-title":"Antibiotics with activity against intestinal anaerobes and the hazard of acquired colonization with ceftriaxone-resistant Gram-negative pathogens in ICU patients: a propensity score-based analysis","volume":"74","author":"Boutrot","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R27-20261026","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.cmi.2021.12.003","article-title":"What is the evidence base of used aggregated antibiotic resistance percentages to change empirical antibiotic treatment? A scoping review","volume":"28","author":"Auzin","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R28-20261026","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1473-3099(25)00313-5","article-title":"Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery","volume":"26","author":"Howard","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"R29-20261026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R30-20261026","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1128\/AAC.00867-13","article-title":"Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa","volume":"57","author":"Felton","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20261026","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-020-00919-6","article-title":"Prolonged versus intermittent infusion of \u03b2-lactam antibiotics: a systematic review and meta-regression of bacterial killing in preclinical infection models","volume":"59","author":"Dhaese","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R32-20261026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs intermittent meropenem administration in critically ill patients with sepsis: the MERCY Randomized Clinical Trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"key":"R33-20261026","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III Randomized Clinical Trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"R34-20261026","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"R35-20261026","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R36-20261026","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"R37-20261026","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/jac\/dky314","article-title":"Therapeutic drug monitoring of \u03b2-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures","volume":"73","author":"Wong","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R38-20261026","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"R39-20261026","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"R40-20261026","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial","volume":"48","author":"Ewoldt","year":"2022","journal-title":"Intensive Care Med"},{"key":"R41-20261026","first-page":"e0726","article-title":"\u03b2-lactam therapeutic drug monitoring in critically ill patients: weighing the challenges and opportunities to assess clinical value","volume":"4","author":"Dilworth","year":"2022","journal-title":"Crit Care Explor"},{"key":"R42-20261026","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/cid\/ciaf038","article-title":"Translating pharmacokinetic\u2013pharmacodynamic principles into improved methodology for clinical trials that compare intermittent with prolonged infusion of beta-lactam antibiotics","volume":"80","author":"Tilanus","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R43-20261026","doi-asserted-by":"crossref","first-page":"e941","DOI":"10.1097\/CCM.0000000000006622","article-title":"Cystatin C-guided dosing nomogram improves target attainment for cefepime in the critically ill","volume":"53","author":"Barreto","year":"2025","journal-title":"Crit Care Med"},{"key":"R44-20261026","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00134-019-05866-w","article-title":"Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)","volume":"46","author":"Tabah","year":"2020","journal-title":"Intensive Care Med"},{"key":"R45-20261026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00134-013-3077-7","article-title":"De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock","volume":"40","author":"Garnacho-Montero","year":"2014","journal-title":"Intensive Care Med"},{"key":"R46-20261026","doi-asserted-by":"crossref","first-page":"102946","DOI":"10.1016\/j.jiac.2026.102946","article-title":"Clinical impact of antimicrobial de-escalation in critically ill patients: a single-center cohort study","volume":"32","author":"Makino","year":"2026","journal-title":"J Infect Chemother"},{"key":"R47-20261026","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1473-3099(23)00686-2","article-title":"Efficacy and safety of a structured de-escalation from antipseudomonal \u03b2-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial","volume":"24","author":"L\u00f3pez-Cort\u00e9s","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"R48-20261026","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s00134-020-06111-5","article-title":"Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study","volume":"46","author":"De Bus","year":"2020","journal-title":"Intensive Care Med"},{"key":"R49-20261026","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/cid\/ciae591","article-title":"Epidemiology and outcomes of antibiotic de-escalation in patients with suspected sepsis in US hospitals","volume":"80","author":"Kam","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R50-20261026","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/jamainternmed.2025.6919","article-title":"Antibiotic de-escalation in adults hospitalized for community-onset sepsis","volume":"186","author":"Gupta","year":"2026","journal-title":"JAMA Intern Med"},{"key":"R51-20261026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2023.12.003","article-title":"Novel and rapid diagnostics for common infections in the critically ill patient","volume":"38","author":"Pickens","year":"2024","journal-title":"Infect Dis Clin North Am"},{"key":"R52-20261026","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-2600(22)00086-8","article-title":"Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial","volume":"10","author":"Darie","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R53-20261026","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00134-025-08014-9","article-title":"Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial","volume":"51","author":"Voiriot","year":"2025","journal-title":"Intensive Care Med"},{"key":"R54-20261026","first-page":"e1220","article-title":"Diagnostic performance and impact on antimicrobial treatment of a multiplex polymerase chain reaction in critically ill patients with pneumonia: a multicenter observational study (The MORICUP-PCR Study: Morocco ICU Pneumonia-PCR study)","volume":"7","author":"Aissaoui","year":"2025","journal-title":"Crit Care Explor"},{"key":"R55-20261026","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/antibiotics14111084","article-title":"RAPID-CARE: rapid antibiotic optimization in the ICU after implementation of a pneumonia multiplex PCR test\u2014a real-world evaluation","volume":"14","author":"Rodr\u00edguez-G\u00f3mez","year":"2025","journal-title":"Antibiotics"},{"key":"R56-20261026","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00134-024-07772-2","article-title":"INHALE WP3, a multicentre, open-label, pragmatic randomised controlled trial assessing the impact of rapid, ICU-based, syndromic PCR, versus standard-of-care on antibiotic stewardship and clinical outcomes in hospital-acquired and ventilator-associated pneumonia","volume":"51","author":"Enne","year":"2025","journal-title":"Intensive Care Med"},{"key":"R57-20261026","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/antibiotics14040358","article-title":"Optimizing antibiotic treatment duration for ESBL-producing Enterobacteriaceae Bacteremia in ICU: a multicentric retrospective cohort study","volume":"14","author":"Le Berre","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"R58-20261026","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","article-title":"Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections","volume":"392","year":"2025","journal-title":"New Engl J Med"},{"key":"R59-20261026","doi-asserted-by":"crossref","first-page":"155361","DOI":"10.1016\/j.jcrc.2025.155361","article-title":"Seven days versus extended duration antibiotic therapy for multidrug-resistant gram-negative bacterial infections in critically ill patients: a pooled analysis of the OPTIMISE and REGARD-VAP trials","volume":"92","author":"Umer","year":"2026","journal-title":"J Crit Care"},{"key":"R60-20261026","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00134-025-07857-6","article-title":"Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database","volume":"51","author":"Gajdos","year":"2025","journal-title":"Intensive Care Med"},{"key":"R61-20261026","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2024.26458","article-title":"Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-Sepsis Randomized Clinical Trial","volume":"333","author":"Dark","year":"2025","journal-title":"JAMA"},{"key":"R62-20261026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(23)00418-6","article-title":"Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial","volume":"12","author":"Mo","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R63-20261026","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jointm.2022.10.001","article-title":"Antimicrobial stewardship in the intensive care unit","volume":"3","author":"Ture","year":"2023","journal-title":"J Intensive Med"},{"key":"R64-20261026","doi-asserted-by":"crossref","first-page":"102898","DOI":"10.1016\/j.jiac.2025.102898","article-title":"The effect of pharmacist-led antimicrobial stewardship on antimicrobial use in an intensive care unit: a single-center, retrospective, observational study","volume":"32","author":"Nishita","year":"2026","journal-title":"J Infect Chemother"},{"key":"R65-20261026","doi-asserted-by":"crossref","first-page":"1513408","DOI":"10.3389\/fcimb.2024.1513408","article-title":"Rapid diagnostic testing combined with an immediate infectious disease consultation increases the rate of septic intensive care unit patients on targeted antibiotic therapy","volume":"14","author":"Kramme","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"R66-20261026","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13054-025-05653-8","article-title":"Optimal antibiotic use in the intensive care unit","volume":"29","author":"Micek","year":"2025","journal-title":"Crit Care"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCC.0000000000001389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:00:26Z","timestamp":1792994426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MCC.0000000000001389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000001389","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}